(Q37968531)

26 August 2017

title

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? (English)

1 reference

myeloproliferative neoplasm

26 August 2017

1 reference

1 reference

Madappa N Kundranda

1

1 reference

26 August 2017

Raoul Tibes

series ordinal

2

1 reference

26 August 2017

Ruben A Mesa

series ordinal

3

1 reference

26 August 2017

publication date

1 March 2012

1 reference

Current hematologic malignancy reports

26 August 2017

published in

1 reference

26 August 2017

volume

7

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

78-86

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-011-0107-9

26 August 2017

exact match

0 references

cites work

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

A road map for those who don't know JAK-STAT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Risk factors for leukemic transformation in patients with primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Unraveling the molecular pathophysiology of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Nuclear translocation of urokinase-type plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Taxing sugar-sweetened beverages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0107-9

Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years

21 January 2018

1 reference

12 December 2020

Some speculations on the myeloproliferative syndromes.

1 reference

12 December 2020

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

1 reference

12 December 2020

What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?

1 reference

12 December 2020

Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia

1 reference

12 December 2020

Use and risks of phosphorus-32 in the treatment of polycythaemia vera

1 reference

12 December 2020

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

1 reference

12 December 2020

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

12 December 2020

CONTRASTING INCIDENCE OF ACUTE MONOCYTIC AND GRANULOCYTIC LEUKEMIAS IN P32-TREATED PATIENTS WITH POLYCYTHEMIA VERA AND CHRONIC LYMPHOCYTIC LEUKEMIA

1 reference

12 December 2020

Genetic complexity of myeloproliferative neoplasms.

1 reference

12 December 2020

Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms

1 reference

12 December 2020

Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders

1 reference

12 December 2020

Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.

1 reference

12 December 2020

10.1007/S11899-011-0107-9

Identifiers

DOI

1 reference

26 August 2017

1 reference